Celebrating two decades in pharmaceutical manufacturing with a new tablet press.

  • Piramal Pharma Solutions celebrates 20 years in the industry.
  • New Korsch X3 tablet press enhances manufacturing capabilities.
  • Expansion initiatives continue at the Morpeth facility.

Piramal Pharma Solutions is celebrating its 20th anniversary at its Morpeth facility, marking a significant milestone in pharmaceutical manufacturing. The company has announced the procurement of a new Korsch X3 tablet press, aimed at enhancing its production capabilities. This investment reflects Piramal's commitment to advancing its manufacturing processes and maintaining high-quality standards in the industry.

The new Korsch X3 tablet press is designed to improve efficiency and scalability in tablet production. By upgrading their equipment, Piramal Pharma Solutions aims to meet the growing demands of the pharmaceutical market. This acquisition is part of a broader strategy to evolve and expand their operations while ensuring compliance with industry regulations.

Piramal Pharma Solutions' Morpeth facility has been instrumental in the company’s growth over the past two decades. The introduction of advanced machinery like the Korsch X3 tablet press demonstrates the firm's dedication to innovation and high standards in pharmaceutical manufacturing.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation

Innovative automation enhances cancer research and immunological studies. AI-powered tools improve research…

Services PMI at 53.8 in January 2026, According to ISM Report

January sees strong growth in services sector as PMI remains robust. Services…

Pharmacelera Raises $6M to Expand in US and Enhance Drug Discovery Platform

Funding will support growth and technological advancements in drug discovery. Pharmacelera has…

WuXi Biologics and Vertex Enter Research Agreement for T-Cell Engager

Collaboration focuses on advancing T-cell engager therapies for cancer treatment WuXi Biologics…